These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 16258825

  • 1. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan.
    Kobayashi Y.
    J Infect Chemother; 2005 Oct; 11(5):259-61. PubMed ID: 16258825
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Reliability of disc-diffusion susceptibility testing for arbekacin, vancomycin and teicoplanin against methicillin-resistant Staphylococcus aureus].
    Kouda M, Homma S, Udagawa I, Tamura K, Fukuhara J, Takeuchi M.
    Jpn J Antibiot; 1999 Dec; 52(12):681-9. PubMed ID: 10695023
    [Abstract] [Full Text] [Related]

  • 7. Comparative analysis and validation of different assays for glycopeptide susceptibility among methicillin-resistant Staphylococcus aureus strains.
    Bernard L, Vaudaux P, Rohner P, Huggler E, Armanet M, Pittet D, Lew DP, Schrenzel J.
    J Microbiol Methods; 2004 May; 57(2):231-9. PubMed ID: 15063063
    [Abstract] [Full Text] [Related]

  • 8. [Combination effect of teicoplanin and various antibiotics against hetero-VRSA and VRSA].
    Hanaki H, Hiramatsu K.
    Kansenshogaku Zasshi; 1999 Oct; 73(10):1048-53. PubMed ID: 10565121
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In vitro combined effects of cefozopran/teicoplanin and cefozopran/vancomycin on methicillin-resistant Staphylococcus aureus.
    Toyokawa M, Asari S, Nishi I, Horikawa M, Tsukamoto H, Sunada A, Ueda A, Iwatani Y.
    J Chemother; 2003 Feb; 15(1):31-6. PubMed ID: 12678411
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Low-level resistance to glycopeptides amongst staphylococcus species: surveillance in a university hospital and evaluation of a vancomycin screening agar.
    Park YJ, Jun Park J, Lee SO, Oh EJ, Kee Kim B.
    Diagn Microbiol Infect Dis; 2001 Nov; 41(3):155-9. PubMed ID: 11750170
    [Abstract] [Full Text] [Related]

  • 14. Comparative in vitro activity of vancomycin and other antimicrobial agents against methicillin-resistant staphylococcus aureus and enterococcus faecium in the Tohoku district of Japan.
    Lutfor AB, Kikuchi T, Tokue Y, Takahashi H, Shoji S, Fujimura S, Nukiwa T, Watanabe A.
    Chemotherapy; 1998 Nov; 44(5):318-23. PubMed ID: 9732146
    [Abstract] [Full Text] [Related]

  • 15. [In vitro combination effect of vancomycin and carbapenems against carbapenem-resistant MRSA].
    Sato S, Miura T, Kudo E, Kudo Y, Saitoh Y, Kimpara I, Tsujino M, Kudo H.
    Jpn J Antibiot; 1997 Aug; 50(8):711-6. PubMed ID: 9339397
    [Abstract] [Full Text] [Related]

  • 16. [Investigation of glycopeptide resistance in methicillin resistant staphylococcal isolates].
    Hoşgör Limoncu M, Ermertcan S, Taşli H, Kurutepe S.
    Mikrobiyol Bul; 2007 Oct; 41(4):511-6. PubMed ID: 18173069
    [Abstract] [Full Text] [Related]

  • 17. First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand.
    Trakulsomboon S, Danchaivijitr S, Rongrungruang Y, Dhiraputra C, Susaemgrat W, Ito T, Hiramatsu K.
    J Clin Microbiol; 2001 Feb; 39(2):591-5. PubMed ID: 11158112
    [Abstract] [Full Text] [Related]

  • 18. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals.
    Cartolano GL, Cheron M, Benabid D, Leneveu M, Boisivon A, Association of Hospital Bacteriologists, Virologists and Hygiene Professionals.
    Clin Microbiol Infect; 2004 May; 10(5):448-51. PubMed ID: 15113324
    [Abstract] [Full Text] [Related]

  • 19. Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
    Tarasi A, Cassone M, Monaco M, Tarasi D, Pompeo ME, Venditti M.
    J Chemother; 2003 Jun; 15(3):239-43. PubMed ID: 12868549
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.